159 related articles for article (PubMed ID: 21740948)
1. Venlafaxine in somatopsychic and autopsychic depersonalization.
Preve M; Mula M; Cassano GB; Pini S
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1808-9. PubMed ID: 21740948
[No Abstract] [Full Text] [Related]
2. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder.
Pollack M; Mangano R; Entsuah R; Tzanis E; Simon NM; Zhang Y
Psychopharmacology (Berl); 2007 Oct; 194(2):233-42. PubMed ID: 17589833
[TBL] [Abstract][Full Text] [Related]
3. Venlafaxine and paroxetine in treatment-resistant depression.
Gregson J
Br J Psychiatry; 1999 Dec; 175():591. PubMed ID: 10789369
[No Abstract] [Full Text] [Related]
4. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.
Denys D; van der Wee N; van Megen HJ; Westenberg HG
J Clin Psychopharmacol; 2003 Dec; 23(6):568-75. PubMed ID: 14624187
[TBL] [Abstract][Full Text] [Related]
5. Drug therapy in treatment-resistant depression.
Malhi GS; Farmer AE
Br J Psychiatry; 1999 Oct; 175():390-1. PubMed ID: 10789311
[No Abstract] [Full Text] [Related]
6. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine.
Owens MJ; Krulewicz S; Simon JS; Sheehan DV; Thase ME; Carpenter DJ; Plott SJ; Nemeroff CB
Neuropsychopharmacology; 2008 Dec; 33(13):3201-12. PubMed ID: 18418363
[TBL] [Abstract][Full Text] [Related]
7. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial.
Denys D; Van Nieuwerburgh F; Deforce D; Westenberg HG
J Clin Psychiatry; 2007 May; 68(5):747-53. PubMed ID: 17503984
[TBL] [Abstract][Full Text] [Related]
8. Drug treatment for resistant depression.
Daniels S
Br J Psychiatry; 2000 Apr; 176():398. PubMed ID: 10827893
[No Abstract] [Full Text] [Related]
9. The use of newer antidepressants for panic disorder.
Gorman JM
J Clin Psychiatry; 1997; 58 Suppl 14():54-8; discussion 59. PubMed ID: 9418747
[TBL] [Abstract][Full Text] [Related]
10. Combined antidepressants and CBT for panic disorder with agoraphobia.
Coupland NJ
J Psychiatry Neurosci; 2008 Mar; 33(2):176. PubMed ID: 18330461
[No Abstract] [Full Text] [Related]
11. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.
Richard IH; McDermott MP; Kurlan R; Lyness JM; Como PG; Pearson N; Factor SA; Juncos J; Serrano Ramos C; Brodsky M; Manning C; Marsh L; Shulman L; Fernandez HH; Black KJ; Panisset M; Christine CW; Jiang W; Singer C; Horn S; Pfeiffer R; Rottenberg D; Slevin J; Elmer L; Press D; Hyson HC; McDonald W;
Neurology; 2012 Apr; 78(16):1229-36. PubMed ID: 22496199
[TBL] [Abstract][Full Text] [Related]
12. Selective serotonin reuptake inhibitors combined with venlafaxine in depressed patients who had partial response to venlafaxine: four cases.
Gonul AS; Akdeniz F; Donat O; Vahip S
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Aug; 27(5):889-91. PubMed ID: 12921926
[TBL] [Abstract][Full Text] [Related]
13. Serotonin reuptake inhibitors in Raynaud's phenomenon.
Jaffe IA
Lancet; 1995 May; 345(8961):1378. PubMed ID: 7752794
[No Abstract] [Full Text] [Related]
14. Dosing by side effect threshold: two cases of panic disorder responsive to low-dose venlafaxine.
Orenstein H; Raskind MA
J Clin Psychiatry; 2010 Jan; 71(1):89-91. PubMed ID: 20129010
[No Abstract] [Full Text] [Related]
15. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
Trivedi MH; Wan GJ; Mallick R; Chen J; Casciano R; Geissler EC; Panish JM
J Clin Psychopharmacol; 2004 Oct; 24(5):497-506. PubMed ID: 15349005
[TBL] [Abstract][Full Text] [Related]
16. Topiramate in venlafaxine-induced visual hallucinations in an obese patient with a posterior cerebral artery infarction.
Anghelescu I; Klawe C; Himmerich H; Szegedi A
J Clin Psychopharmacol; 2001 Aug; 21(4):462-4. PubMed ID: 11476137
[No Abstract] [Full Text] [Related]
17. [Venlafaxine (velaxin) effectivity in treatment of depression: results of the recent investigations].
Veltishchev DY
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(11 Pt 2):79-81. PubMed ID: 24429970
[No Abstract] [Full Text] [Related]
18. Use of venlafaxine in other psychiatric disorders.
Ninan PT
Depress Anxiety; 2000; 12 Suppl 1():90-4. PubMed ID: 11098421
[TBL] [Abstract][Full Text] [Related]
19. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.
Thase ME; Entsuah AR; Rudolph RL
Br J Psychiatry; 2001 Mar; 178():234-41. PubMed ID: 11230034
[TBL] [Abstract][Full Text] [Related]
20. Venlafaxine for treatment of obsessive-compulsive disorder.
Ananth J; Burgoyne K; Smith M; Swartz R
Am J Psychiatry; 1995 Dec; 152(12):1832. PubMed ID: 8526258
[No Abstract] [Full Text] [Related]
[Next] [New Search]
